NEWS | BEAM Alliance


Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains

• The Institut Pasteur will provide a selection of strains for the DEINOVE platform to evaluate their potential antibiotic and antifungal activities.
• This agreement fits into the AGIR program, which aims at studying a wide range of bacterial strains to optimize opportunities for discovering novel antibiotic structures.

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, has announced that it will benefit from the Institut Pasteur’s provision of biological resources for the research of new antimicrobial agents from original strains.
The Institut Pasteur, one of the most renowned worldwide players in the area of infectious disease research, will entrust a targeted selection of strains from their bacterial collection to DEINOVE.
As part of their AGIR program (Antibiotics against Resistant Infectious Germs), DEINOVE will assess the strains’ antimicrobial properties on their technology platform.

Full PR available here